<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004880</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067542</org_study_id>
    <secondary_id>UCLA-9703025</secondary_id>
    <secondary_id>NCI-G00-1675</secondary_id>
    <nct_id>NCT00004880</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Advanced Kidney Cancer</brief_title>
  <official_title>A Phase I Pilot Trial of a Multi-Antigen Loaded Dendritic Cell Vaccine for the Treatment of Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who&#xD;
      have advanced kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the safety of multiantigen loaded dendritic cells (DC) vaccine in&#xD;
      patients with advanced renal cell carcinoma. II. Evaluate the immunologic response to this&#xD;
      regimen in this patient population. III. Evaluate the clinical response to this regimen in&#xD;
      this patient population.&#xD;
&#xD;
      OUTLINE: This is a sequential cohort study. All patients undergo total nephrectomy to harvest&#xD;
      primary tumor for vaccine preparation. Patients without primary tumor undergo surgical&#xD;
      resection of the accessible metastatic site for vaccine preparation. Patients are assigned to&#xD;
      1 of 4 treatment arms. Arm I: Patients receive vaccination with irradiated autologous tumor&#xD;
      lysate (TuLy) intradermally (ID) on day 0 followed by vaccination with multiantigen liposome&#xD;
      loaded dendritic cells (DC) ID on days 7, 14, and 21. Arm II: Patients receive vaccinations&#xD;
      as in arm I, except DC are pulsed with tumor cells. Arm III: Patients receive vaccination&#xD;
      with irradiated autologous tumor lysate (TuLy) IV on day 0 followed by vaccination with&#xD;
      multiantigen liposome loaded DC IV on days 7, 14, and 21. Arm IV: Patients receive&#xD;
      vaccinations as in arm III, except DC are treated as in arm II. Patients are followed on days&#xD;
      28, 42, 70, and 112.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">14</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dendritic cell vaccine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell carcinoma Evaluable or bidimensionally&#xD;
             measurable disease with primary renal tumor in place or surgically accessible&#xD;
             metastatic site greater than 2 x 2 cm&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Hematopoietic:&#xD;
&#xD;
               -  Hemoglobin at least 10 g/dL (not transfusion dependent)&#xD;
&#xD;
               -  Platelet count at least 75,000/mm3&#xD;
&#xD;
               -  WBC greater than 3,000/mm3&#xD;
&#xD;
          -  Hepatic: SGOT/SGPT no greater than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 mg/dL&#xD;
&#xD;
          -  Renal: Creatinine no greater than 2.0 g/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 14 days since prior acute therapy for infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncontrolled CNS metastasis&#xD;
&#xD;
          -  ischemic heart disease that precludes surgery&#xD;
&#xD;
          -  pulmonary condition that precludes surgery&#xD;
&#xD;
          -  other underlying condition or allergy that would preclude study&#xD;
&#xD;
          -  acute viral, bacterial, or fungal infection requiring therapy HIV negative&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  other acute medical problems that would preclude study&#xD;
&#xD;
          -  concurrent corticosteroids (oral, topical, inhaled)&#xD;
&#xD;
          -  prior organ allografts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J. Gitlitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

